Meningococcal vaccine coverage among population in France 2019-2020, by age
In 2020, vaccination coverage against meningococcal C in France reached 89.9 percent among children aged 24 months, 80.8 percent among children aged two to four, 75.3 percent among five to nine year olds, 59.2 percent among 10 to 14 year olds, and 37.8 percent among 15 to 19 year olds. Between 2019 and 2020, meningococcal vaccination coverage increased in all age groups across the country.
Meningococcus is a bacterium found in the throat and nose. Most often, it does not cause disease. Sometimes it is responsible for serious infections, such as meningitis, in children and young adults. These infections exist worldwide. There are several types of meningococci. In France, types B and C are the most common, vaccination against it is mandatory for infants since January 1, 2018. For infants, the vaccine strategy is to administer a first dose at the age of 5 months, followed by a second dose at the age of 12 months. Passed 12 months and until the age of 24, an additional vaccine dose is administered for those who did not receive the primary dose.
Meningococcus is a bacterium found in the throat and nose. Most often, it does not cause disease. Sometimes it is responsible for serious infections, such as meningitis, in children and young adults. These infections exist worldwide. There are several types of meningococci. In France, types B and C are the most common, vaccination against it is mandatory for infants since January 1, 2018. For infants, the vaccine strategy is to administer a first dose at the age of 5 months, followed by a second dose at the age of 12 months. Passed 12 months and until the age of 24, an additional vaccine dose is administered for those who did not receive the primary dose.
